Table 1 Clinical and histological findings for 85 patients with myxofibrosarcoma/undifferentiated sarcoma.

Male/Female, n

62/23

Mitosis (10 HPFs)**

15 (7–32)

(0, 87)

Age, years*

70 ± 14

(18, 96)

Necrosis, %**

10 (0–30)

(0, 80)

Tumor size, mm*

91 ± 49

(18, 290)

Vascular invasion, n

V0

70

Location, n

Thigh

35

V1

15

Lower leg

12

Sickle-shaped vascular**

10 (2–52)

(0, 1252)

Upper arm

10

G1 (0–99), n

72

Forearm

7

G2 (100-), n

13

Shoulder

4

Myxoid area, %*

29 ± 37

(0.3, 100)

Inguinal region

1

Myxoid area, n

0%

35

Back

4

0.1– 0.9%

4

Chest

4

1–49%

15

Buttocks

5

≧ 50%

31

Foot

1

INF a/b/c, n

43/24/18

Abdomen

2

Tail-like infiltration length (TIL), mm*

6 ± 10

(0, 45)

Dermis/Subcutaneous fatty tissue/Muscle

18/28/39

Cellularity, Low/Medium/High, n

15/34/36

Margin, n

Positive (R1)

34

Hemorrhage area, %**

10 (0–20)

(0, 80)

Negative (R0)

51

Fibrotic change, %**

10 (10–30)

(0, 60)

Local recurrence, n

22

Pleomorphic component, %**

40 (20–80)

(0, 100)

Time to local recurrence, month**

10 (5–21)

(2, 64)

Epithelioid like component, %**

0(0–20)

(0, 100)

Metastasis, n

29

Inflammatory change, inconspicuous/prominent, n

51/34

Time to metastasis, month**

8 (4–17)

(0, 40)

Histiocytes accumulation, inconspicuous/prominent, n

75/10

Metastatic organs, n

Lung

19

Cystic change, inconspicuous/prominent, n

67/18

Soft tissue

5

Rhabdoid cells component, inconspicuous/prominent, n

57/28

Lymph node

3

Giant cell component, inconspicuous/prominent, n

18/67

Brain

1

FNCLCC Grading

G1

13

Retroperitoneum

1

G2

37

G3

35

Follow-up period, months after surgery*

47 ± 34

(6, 164)